Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Glioblastoma 100Glioma 42Brain Neoplasms 28Neuroblastoma 25Astrocytoma 18Gliosarcoma 15Sarcoma, Ewing 12Rhabdomyosarcoma 12Neoplasms 12Recurrence 11Medulloblastoma 11Small Cell Lung Carcinoma 8Sarcoma 8Oligodendroglioma 8Melanoma 7Osteosarcoma 6Ependymoma 6Diffuse Intrinsic Pontine Glioma 6Central Nervous System Neoplasms 4Rhabdoid Tumor 3Prostatic Neoplasms 3Neuroendocrine Tumors 3Neuroectodermal Tumors, Primitive 3Neoplasm Metastasis 3Lymphoma, Follicular 3Lymphoma 3Lung Neoplasms 3Ganglioneuroblastoma 3Desmoplastic Small Round Cell Tumor 3Colorectal Neoplasms 3

Interventions

Midazolam 2Injections 2zanidatamab 1tislelizumab 1sitravatinib 1repaglinide 1pembrolizumab 1pamiparib 1lenvatinib 1drospirenone 1cemiplimab 1Temozolomide 1Pemetrexed 1Paclitaxel 1Ipilimumab 1HMPL-013 1Gemcitabine 1Ethinyl Estradiol 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Advanced Malignancies × Temozolomide × 1 year × Clear all
NCT04164199 2026-06-03

Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies

BeOne Medicines

Phase 3 Completed
404 enrolled

Advanced Malignancies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡